Zoetis Inc. (ZTS) EBITDA Margin: 42.98%
Is Zoetis Inc.’s EBITDA margin high or low?
Zoetis Inc.'s EBITDA margin of 42.98% is in line with its 5-year average of 41.76%, near the high end of its 5-year range (40.24%–43.13%).
The EBITDA margin for Zoetis Inc. (ZTS) is 42.98% as of Tuesday, June 9, 2026. It is above its 12-month average by 1.36% (42.41%).
ZTS EBITDA Margin Chart
ZTS Average EBITDA Margin Chart
ZTS Current vs Average EBITDA Margin Chart
ZTS EBITDA Margin Metrics
EBITDA MARGIN
42.98%
EBITDA MARGIN AVG TTM
42.41%
EBITDA MARGIN AVG 3Y
42.38%
EBITDA MARGIN AVG 5Y
41.76%
EBITDA MARGIN AVG 10Y
37.81%
EBITDA MARGIN AVG 15Y
31.86%
EBITDA MARGIN AVG 20Y
29.99%
CURRENT VS TTM AVG
+1.36%
CURRENT VS 3Y AVG
+1.43%
CURRENT VS 5Y AVG
+2.93%
CURRENT VS 10Y AVG
+13.67%
CURRENT VS 15Y AVG
+34.89%
CURRENT VS 20Y AVG
+43.31%
ZTS Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | — | 42.98% | 42.41% | 42.38% | 41.76% |
| Centene Corporation (CNC) | $32.69B | -2.64% | 0.58% | 1.90% | 2.49% |
| IQVIA Holdings Inc. (IQV) | $31.09B | 21.24% | 21.82% | 21.39% | 20.63% |
| Agilent Technologies, Inc. (A) | $38.26B | 26.41% | 27.60% | 26.98% | 26.47% |
| DexCom, Inc. (DXCM) | $30.17B | 24.96% | 24.20% | 23.29% | 21.36% |
| Biogen Inc. (BIIB) | $29.39B | 31.60% | 31.28% | 30.38% | 32.54% |
| Veeva Systems Inc. (VEEV) | $27.37B | 28.68% | 27.64% | 24.37% | 25.68% |
| Humana Inc. (HUM) | $43.60B | 2.24% | 2.50% | 3.66% | 4.53% |
| Waters Corporation (WAT) | $24.19B | 31.97% | 33.50% | 33.77% | 33.93% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 30.67% | 31.14% | 31.31% | 30.59% |
Margin Comparison
Gross Margin
70.5%
EBITDA Margin
43.0%
Operating Margin
38.0%
Net Margin
28.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Zoetis Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Zoetis Inc. (ZTS)?
- The EBITDA margin for ZTS stock is 42.98%.
- Is Zoetis Inc.'s EBITDA margin high or low?
- Zoetis Inc.'s EBITDA margin of 42.98% is in line with its 5-year average of 41.76%, near the high end of its 5-year range (40.24%–43.13%).
- What is the TTM average EBITDA margin for Zoetis Inc. (ZTS)?
- The TTM average EBITDA margin for ZTS stock is 42.41%.
- What is the 3Y average EBITDA margin for Zoetis Inc. (ZTS)?
- The 3Y average EBITDA margin for ZTS stock is 42.38%.
- What is the 5Y average EBITDA margin for Zoetis Inc. (ZTS)?
- The 5Y average EBITDA margin for ZTS stock is 41.76%.
- What is the 10Y average EBITDA margin for Zoetis Inc. (ZTS)?
- The 10Y average EBITDA margin for ZTS stock is 37.81%.
- What is the 15Y average EBITDA margin for Zoetis Inc. (ZTS)?
- The 15Y average EBITDA margin for ZTS stock is 31.86%.
- What is the 20Y average EBITDA margin for Zoetis Inc. (ZTS)?
- The 20Y average EBITDA margin for ZTS stock is 29.99%.
Zoetis Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 42.98% |
| 2024-12-31 | 41.83% |
| 2023-12-31 | 43.13% |
| 2022-12-31 | 41.56% |
| 2021-12-31 | 40.79% |
| 2020-12-31 | 40.24% |
| 2019-12-31 | 39.22% |
| 2018-12-31 | 37.94% |
| 2017-12-31 | 36.59% |
| 2016-12-31 | 33.43% |
| 2015-12-31 | 18.22% |
| 2014-12-31 | 23.85% |
| 2013-12-31 | 22.14% |
| 2012-12-31 | 21.70% |
| 2011-12-31 | 15.00% |
| 2010-12-31 | 11.17% |
| 2009-12-31 | 0.07% |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck